Effects of strontium fructose 1, 6-diphosphate (FDP-Sr) on didymus lesion and the mRNA expressions of prepro ET-1(PPET-1) and endothelin converting enzyme(ECE) in diabetic rats

Abstract

Abstract: AIM: To determine the benefits of FDP-Sr on streptozotocin (STZ) induced diabetic testopathy in rats, compared with testosterone propionate, and explore its likely mechanisms.METHODS: Male SD rats were given streptozotocin to induce strontium fructose 1, 6-diphosphate (EDP-sr) diabetes for 8 weeks and in the second 4 weeks rats were treated with FDP-Sr (50, 100, 200 mg/kg, i.g.) and testosterone propionate(4 mg/kg, s.c.).GSH-px, mRNA expression of perpro ET-1 (ppET-1), endothelin coverting enzyme(ECE) in testicular tissues, morphological changes and blood testosterone were investigated.RESULTS: Seminiferous tubules in diabetic rats were significantly atrophied relative to the normal.The expressions of ppET-1 and ECE were upregulated significantly in association with decreased serum testosterone and decreased GSH-px significantly.FDP-Sr attenuated these alterations significantly, but testosterone propionate was less effective.CONCLUSION: FDP-Sr relieves diabetes induced male hypogonadism in rats in superior to that of testosterone propionate.It is likely to be related by suppressing over-active endothelin system in the testis.

Key words: diabetes, testopathy, endothelin, strontium fructose 1, 6-diphosphate, testosterone, supplement therapy

CLC Number:

R587.1

ZHANG Qi, TANG Xiao-yun, DAI De-Zai, YING Han-jie, DAI Yin. Effects of strontium fructose 1, 6-diphosphate (FDP-Sr) on didymus lesion and the mRNA expressions of prepro ET-1(PPET-1) and endothelin converting enzyme(ECE) in diabetic rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(12): 1339-1343.

References

[1] Tang XY, Zhang Q, Dai DZ, et al.Effects of strontium fructose 1, 6-diphosphate on expression of apoptosis-related genes and oxidative stress in testes of diabetic rats[J].Int J Urol, 2008, 15(3):251-256.
[2] Feng Y, Zhang Q, Dai DZ, et al.Strontium fructose 1, 6-diphosphate rescues adenine-induced male hypogonadism and upregulates the testicular endothelin-1 system [J]. Clin Exp Pharmacol Physiol, 2007, 34(11):1131-1137.
[3] Filippini A, Tripiciano A, Peluso C, et al.ECE-1 is cyclically expressed in Sertoli cells and mediates the spatiotemporal control of tubular contractility[J].Andrologia, 2000, 32(1):61.
[4] Tripiciano A, Peluso C, Morena AR, et al.Cyclic expression of endothelin-converting enzyme-1 mediates the functional regulation of seminiferous tubule contraction [J].J Cell Biol, 1999, 145(5):1027-1038.
[5] Barone F, Genazzani AA, Conti A, et al.A pivotal role for cADPR-mediated Ca²⁺signaling:regulation of endothelin-induced contraction in peritubular smooth muscle cells[J].FASEB J, 2002, 16(7):697-705.
[6] Tang X, Qi M, Dai D, et al.Effects of CPU 86017 (chlorobenzyltetrahydroberberine chloride) and its enantiomers on thyrotoxicosis-induced overactive endothelin-1 system and oxidative stress in rat testes[J].Urology, 2006, 68(2):455-461.
[7] Cai L, Chen S, Evans T, et al.Apoptotic germ-cell death and testicular damage in experimental diabetes:prevention by endothelin antagonism[J].Urol Res, 2000, 28(5):342-347.
[8] Ergǜn S, Harneit S, Paust HJ, et al.Endothelin and endothelin receptors A and B in the human testis[J].Anat Embryol(Berl), 1999, 199(3):207-214.
[9] Tripiciano A, Palombi F, Ziparo E, et al.Dual control of seminiferous tubule contractility mediated by ETA and ETB endothelin receptor subtypes[J].FASEB J, 1997, 11(4): 276-286.
[10] Romano F, Gambara G, De Cesaris P, et al.Endothelin induces functional hypertrophy of peritubular smooth muscle cells[J].J Cell Physiol, 2007, 212(1):264-273.
[11] Feng Y, Dai DZ, Na T, et al.Endothelin receptor antagonist CPU0213 suppresses ventricular fibrillation in L-thyroxin induced cardiomyopathy[J].Pharmacol Rep, 2007, 59(3):306-314.
[12] Feng Y, Tang XY, Dai DZ, et al.Reversal of isoproterenol-induced downregulation of phospholamban and FKBP12.6 by CPU0213-mediated antagonism of endothelin receptors[J].Acta Pharmacol Sin, 2007, 28(11):1746-1754.
[13] Su W, Dai DZ, Liu HR, et al.Upregulated endothelin system in diabetic vascular dy sfunction and early retinopathy is reversed by CPU0213 and total triterpene acids from Fructus Corni[J].Clin Exp Pharmacol Physiol, 2007, 34(12):1228-1233.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[3]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[4]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[5]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[6]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[7]	DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo. Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
[8]	CAI Jing, PAN Binjing, LIU Jingfang. Research progress on the relationship between hypoglycemic drugs and sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
[9]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[10]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[11]	ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin. Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
[12]	LI Hao, LI Ling, XIA Zhiping, YE Qifa, PENG Guizhu. FXR agonist GW4064 ameliorates tacrolimus-induced abnormalities in glucose metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 466-472.
[13]	SHAO Xi, YU Yanan, HUANG Yuhan, WANG Xiaotong, LING Hongwei, LV Dongmei, WANG Tao. Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 287-294.
[14]	LV Xiaohan, LIN Rong. Association of Lin28 with tumor, cardiovascular disease and diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 205-211.
[15]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.